REFERENCES
1. Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41:1551-66.
2. Wang X, Jing J. Cancer immunotherapy in combination with radiotherapy and/or chemotherapy: mechanisms and clinical therapy. MedComm. 2025;6:e70346.
3. Zhou M, Wang J, Pan J, et al. Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy. Nat Commun. 2023;14:3593.
4. Yan W, Lang T, Yuan W, Yin Q, Li Y. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. Acta Pharmacol Sin. 2022;43:3045-54.
5. Xiao Z, Todd L, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14:5110.
6. Dong Y, Li J, Dai Y, et al. Redox-responsive metal-organic framework nanocapsules enhance tumor chemo-immunotherapy by modulating tumor metabolic reprogramming. Materials Today Bio. 2025;31:101487.
7. Jiang M, Yang Z, Dai J, et al. Intratumor microbiome: selective colonization in the tumor microenvironment and a vital regulator of tumor biology. MedComm. 2023;4:e376.
8. Yang M, Tao L, Jiang Y, et al. Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma. Cancer Res. 2020;80:1991-2003.
9. Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19:439-53.
10. Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol. 2021;9:645593.
11. Victorelli S, Passos JF. Telomeres and cell senescence - size matters not. EBioMedicine. 2017;21:14-20.
12. Li M, You L, Xue J, Lu Y. Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved DNA damage response: a mini review. Front Pharmacol. 2018;9:522.
13. Marin I, Boix O, Garcia-Garijo A, et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 2023;13:410-31.
14. Marin I, Serrano M, Pietrocola F. Cellular senescence enhances adaptive anticancer immunosurveillance. OncoImmunology. 2022;12:2154115.
15. Liu Y, Yu Y, Chen Y, Zhuang J, Sun C. Tumor immunosenescence driven by chronic inflammation: mechanisms, microenvironment remodeling and therapeutic strategies. Aging Dis. 2025;17:1347-70.
16. Hayflick L, Moorhead P. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
17. Yamauchi S, Takahashi A. Cellular senescence: mechanisms and relevance to cancer and aging. J Biochem. 2025;177:163-9.
19. Shang D, Sun D, Shi C, et al. Activation of epidermal growth factor receptor signaling mediates cellular senescence induced by certain pro-inflammatory cytokines. Aging Cell. 2020;19:e13145.
20. Michaloglou C, Vredeveld LCW, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720-4.
21. Chicas A, Wang X, Zhang C, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell. 2010;17:376-87.
22. Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15:978-90.
23. Mchugh D, Durán I, Gil J. Senescence as a therapeutic target in cancer and age-related diseases. Nat Rev Drug Discov. 2024;24:57-71.
24. Tabasso A, Jones D, Jones G, Macip S. Radiotherapy-induced senescence and its effects on responses to treatment. Clin Oncol. 2019;31:283-9.
25. Frippiat C, Chen QM, Zdanov S, Magalhaes J, Remacle J, Toussaint O. Subcytotoxic H2O2 stress triggers a release of transforming growth factor-β1, which induces biomarkers of cellular senescence of human diploid fibroblasts. J Biol Chem. 2001;276:2531-7.
26. Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340-55.
27. Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531-50.
28. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559-72.
29. Belle JI, Sen D, Baer JM, et al. Senescence defines a distinct subset of myofibroblasts that orchestrates immunosuppression in pancreatic cancer. Cancer Discov. 2024;14:1324-55.
30. Takeuchi S, Takahashi A, Motoi N, et al. Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo. Cancer Res. 2010;70:9381-90.
31. Ogrodnik M, Carlos Acosta J, Adams PD, et al. Guidelines for minimal information on cellular senescence experimentation in vivo. Cell. 2024;187:4150-75.
32. Corpet A, Stucki M. Chromatin maintenance and dynamics in senescence: a spotlight on SAHF formation and the epigenome of senescent cells. Chromosoma. 2014;123:423-36.
33. Vizioli MG, Liu T, Miller KN, et al. Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence. Genes Dev. 2020;34:428-45.
34. Xiang W, Wang S, Pan Y, Cong X, Lu J, Zhang Y. Cytoplasmic chromatin fragments: divergent roles in senescence and cancer. Ageing Cancer Res Treat. 2024;3:202523.
35. Rodier F, Coppé J, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973-9.
36. Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017;9:955-63.
37. Dörr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013;501:421-5.
38. Wiley CD, Campisi J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat Metab. 2021;3:1290-301.
39. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019-31.
40. Parrinello S, Coppe J, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118:485-96.
41. Meng Q, Chen C, Yang N, et al. Surfaceome analysis of extracellular vesicles from senescent cells uncovers uptake repressor DPP4. Proc Natl Acad Sci USA. 2023;120:e2219801120.
42. Terlecki-Zaniewicz L, Lämmermann I, Latreille J, et al. Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype. Aging. 2018;10:1103-32.
43. Elder SS, Emmerson E. Senescent cells and macrophages: key players for regeneration? Open Biol. 2020;10:200309.
44. Reynolds LE, Maallin S, Haston S, Martinez-Barbera JP, Hodivala-Dilke KM, Pedrosa AR. Effects of senescence on the tumour microenvironment and response to therapy. FEBS J. 2023;291:2306-19.
45. Zhang J, He T, Xue L, Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409.
46. Huang M, Wang Y, Fang L, et al. T cell senescence: a new perspective on immunotherapy in lung cancer. Front Immunol. 2024;15:1338680.
47. Janelle V, Neault M, Lebel M, et al. p16INK4a regulates cellular senescence in PD-1-expressing human T cells. Front Immunol. 2021;12:698565.
48. Wada H, Otsuka R, Germeraad WTV, Murata T, Kondo T, Seino K. Tumor cell-induced macrophage senescence plays a pivotal role in tumor initiation followed by stable growth in immunocompetent condition. J Immunother Cancer. 2023;11:e006677.
49. Shen W, Huang Y, Yang X, et al. Senescent macrophages in tumor: phenotypes, roles, and interventions. Cell Death Dis. 2025;16:677.
50. Assouline B, Kahn R, Hodali L, et al. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Nat Commun. 2024;15:6162.
51. Wang B, Han J, Elisseeff JH, Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024;25:958-78.
52. Wang T, Notta F, Navab R, et al. Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes. Mol Cancer Res. 2017;15:3-14.
53. Zhou T, Yan J, Mao G, et al. Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring. Cancer Discov. 2026;16:1550-72.
54. Bloom SI, Islam MT, Lesniewski LA, Donato AJ. Mechanisms and consequences of endothelial cell senescence. Nat Rev Cardiol. 2022;20:38-51.
55. Wang D, Xiao F, Feng Z, et al. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence. Breast Cancer Res. 2020;22:103.
56. Hwang HJ, Lee Y, Kang D, et al. Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells. Cancer Lett. 2020;490:100-10.
57. Liu D, Wang J, Wei Y, et al. Senescent cancer cells in immune surveillance and evasion: mechanisms and therapeutic implications. J Leukocyte Biol. 2025;117:qiaf125.
58. Uzhachenko RV, Bharti V, Ouyang Z, et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 2021;35:108944.
59. Sagiv A, Burton DGA, Moshayev Z, et al. NKG2D ligands mediate immunosurveillance of senescent cells. Aging. 2016;8:328-44.
60. Ruscetti M, Morris JP, Mezzadra R, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020;181:424-41.e21.
61. Yin K, Patten D, Gough S, et al. Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance. Genes Dev. 2022;36:533-49.
62. Xiong J, Dong L, Lv Q, et al. Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes. Clin Transl Med. 2024;14:e1772.
63. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9.
64. Wang T, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature. 2022;611:358-64.
65. Salminen A. Inhibitory immune checkpoints suppress the surveillance of senescent cells promoting their accumulation with aging and in age-related diseases. Biogerontology. 2024;25:749-73.
66. Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78:120-9.
67. Krouwer VJD, Hekking LHP, Langelaar-Makkinje M, Regan-Klapisz E, Post J. Endothelial cell senescence is associated with disrupted cell-cell junctions and increased monolayer permeability. Vasc Cell. 2012;4:12.
68. Tengesdal IW, Dinarello A, Powers NE, et al. Tumor NLRP3-derived IL-1β drives the IL-6/STAT3 axis resulting in sustained MDSC-mediated immunosuppression. Front Immunol. 2021;12:661323.
69. Franzin R, Stasi A, Castellano G, Gesualdo L. Methods for characterization of senescent circulating and tumor-infiltrating T-cells: an overview from multicolor flow cytometry to single-cell RNA sequencing. Methods Mol Biol. 2021;2325:79-95.
70. Wang P, Zhang Y, Cai Q, et al. Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia. Ann Med. 2023;55:2201507.
71. Liu W, Stachura P, Xu HC, et al. Senescent tumor CD8+ T cells: mechanisms of induction and challenges to immunotherapy. Cancers. 2020;12:2828.
72. Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2017;553:96-100.
73. He D, Wu Q, Tian P, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025;43:1622-36.e7.
74. Coppé J, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:e301.
75. Wang N, Fang Y, Hou Y, et al. Senescent cells promote breast cancer cells motility by secreting GM-CSF and bFGF that activate the JNK signaling pathway. Cell Commun Signal. 2024;22:478.
76. Guccini I, Revandkar A, D'ambrosio M, et al. Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021;39:68-82.e9.
77. Capparelli C, Guido C, Whitaker-Menezes D, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. Cell Cycle. 2014;11:2285-302.
78. Zhang D, Zhang J, Xu H, et al. Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation. Mol Cancer. 2024;23:70.
79. Ritschka B, Storer M, Mas A, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 2017;31:172-83.
80. Cole AR, Buj R, Uboveja A, et al. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026;6:1647-66.
81. Kim YH, Choi YW, Lee J, Soh EY, Kim J, Park TJ. Senescent tumor cells lead the collective invasion in thyroid cancer. Nat Commun. 2017;8:15208.
82. Yang L, Fang J, Chen J. Tumor cell senescence response produces aggressive variants. Cell Death Discov. 2017;3:17049.
83. Krtolica A, Parrinello S, Lockett S, Desprez P, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA. 2001;98:12072-7.
84. Angelini PD, Fluck MFZ, Pedersen K, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 2013;73:450-8.
85. Choi YW, Kim YH, Oh SY, et al. Senescent tumor cells build a cytokine shield in colorectal cancer. Adv Sci. 2021;8:2002497.
86. Li H, Zhao R, Wan L, et al. Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging. Nat Aging. 2026;6:1042-63.
87. Lai P, Liu L, Bancaro N, et al. Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. Immunity. 2025;58:811-25.e7.
88. Gallanis G, Sharif G, Schmidt M, et al. Stromal senescence following treatment with the CDK4/6 inhibitor palbociclib alters the lung metastatic niche and increases metastasis of drug-resistant mammary cancer cells. Cancers. 2023;15:1908.
89. Ra Borzone F, Bel Giorello M, Marcelo Martinez L, et al. Senescent mesenchymal stem/stromal cells in pre-metastatic bone marrow of untreated advanced breast cancer patients. Oncol Res. 2023;31:361-74.
90. Fane ME, Chhabra Y, Alicea GM, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022;606:396-405.
91. Kaur A, Ecker BL, Douglass SM, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 2019;9:64-81.
92. Gomes AP, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression. Nature. 2020;585:283-7.
93. Turrell FK, Orha R, Guppy NJ, et al. Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse. Nat Cancer. 2023;4:468-84.
94. Kines KT, Fairchild HR, Elder AM, et al. Aging-induced semaphorin 7a promotes TGF-β1-mediated cell plasticity and breast tumor metastases. Cell Rep. 2025;44:116042.
95. Patel AAH, Dzanan JJ, Ali KX, et al. Ageing promotes metastasis via activation of the integrated stress response. Nature. 2026;652:1339-48.
96. Ecker BL, Kaur A, Douglass SM, et al. Age-related changes in HAPLN1 increase lymphatic permeability and affect routes of melanoma metastasis. Cancer Discov. 2019;9:82-95.
97. Marino-Bravante GE, Carey AE, Hüser L, et al. Age-dependent loss of HAPLN1 erodes vascular integrity via indirect upregulation of endothelial ICAM1 in melanoma. Nat Aging. 2024;4:350-63.
98. Qi X, Jiang L, Cao J. Senotherapies: a novel strategy for synergistic anti-tumor therapy. Drug Discov Today. 2022;27:103365.
99. Troiani M, Colucci M, D’ambrosio M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun. 2022;13:2177.
100. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15:428-35.
101. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14:644-58.
102. Nambiar A, Kellogg D, Justice J, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. eBioMedicine. 2023;90:104481.
103. Silva M, Wacker DA, Driver BE, et al. Senolytics to slow progression of sepsis (stop-sepsis) in elderly patients: study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials. 2024;25:698.
105. Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127-32.
106. Yoshida S, Nakagami H, Hayashi H, et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat Commun. 2020;11:2482.
107. Ohtani N. The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis? Inflamm Regener. 2022;42:11.
108. Li H, Cai R, Zhou Y, Jiang Y, Tan S. cGAS-STING signaling in brain aging and neurodegeneration: molecular links and therapeutic perspectives. J Neuroinflamm. 2025;22:235.
109. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging. 2010;2:344-52.
110. Laberge R, Sun Y, Orjalo AV, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049-61.
111. Budamagunta V, Manohar-Sindhu S, Yang Y, et al. Senescence-associated hyper-activation to inflammatory stimuli in vitro. Aging. 2021;13:19088-107.
112. Abdelgawad IY, Agostinucci K, Sadaf B, Grant MKO, Zordoky BN. Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in doxorubicin-induced senescent endothelial cells. Front Aging. 2023;4:1170434.
113. Sayegh S, Fantecelle CH, Laphanuwat P, et al. Vitamin3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Aging Cell. 2024;23:e14093.
114. Wan M, Gray-Gaillard EF, Elisseeff JH. Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration. Bone Res. 2021;9:41.
115. Dong Z, Luo Y, Yuan Z, Tian Y, Jin T, Xu F. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer. 2024;23:181.
116. Lee CH, Minh Nguyen T, Lee Y, et al. Therapy-induced senescence (TIS) and SASP: the p53-mediated interplay in cancer progression and treatment. Int J Mol Sci. 2025;27:357.
117. Šmahel M. PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int J Mol Sci. 2017;18:1331.
118. Li Y, Li Z, Tang Y, et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer. 2024;12:e009934.
119. Shi H, Xiao M, Li Y, et al. The role of senescence, its therapeutic relevance and clinical implications in the tumor microenvironment. Theranostics. 2025;15:8675-703.
120. Haston S, Gonzalez-Gualda E, Morsli S, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. 2023;41:1242-60.e6.
121. Lee S, Yu Y, Trimpert J, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. 2021;599:283-9.
122. Zhang Y, Tang L, Lu J, Xu L, Cheng B, Xiong J. ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy. BMC Geriatr. 2021;21:225.
123. Saccon TD, Nagpal R, Yadav H, et al. Senolytic combination of dasatinib and quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice. J Gerontol. 2021;76:1895-905.
124. Rawji KS, Young AM, Ghosh T, et al. Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol. 2020;139:893-909.
125. He D, Wu H, Xiang J, et al. Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway. Nat Commun. 2020;11:37.
126. Henson SM, Lanna A, Riddell NE, et al. p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells. J Clin Investig. 2014;124:4004-16.
127. Beck J, Turnquist C, Horikawa I, Harris C. Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms. Carcinogenesis. 2020;41:1017-29.
128. Liu X, Hartman CL, Li L, et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci Transl Med. 2021;13:eaaz6314.
129. Jeng MY, Hull PA, Fei M, et al. Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med. 2018;215:51-62.
130. Globig A, Zhao S, Roginsky J, et al. The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622:383-92.
131. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397-408.
132. González-Gualda E, Baker AG, Fruk L, Muñoz-Espín D. A guide to assessing cellular senescence in vitro and in vivo. FEBS J. 2020;288:56-80.
133. Kohli J, Wang B, Brandenburg SM, et al. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021;16:2471-98.
134. Handa M, Singh A, Flora SJS, Shukla R. Stimuli-responsive polymeric nanosystems for therapeutic applications. Curr Pharm Des. 2022;28:910-21.
135. González-Gualda E, Pàez-Ribes M, Lozano-Torres B, et al. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell. 2020;19:e13142.
136. Guerrero A, Guiho R, Herranz N, et al. Galactose-modified duocarmycin prodrugs as senolytics. Aging Cell. 2020;19:e13133.
137. Khan S, Zhang X, Lv D, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938-47.
138. Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed. 2016;55:1966-73.
139. Inuzuka H, Liu J, Wei W, Rezaeian A. PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives. Acta Mater Med. 2022;1:24-41.
140. He Y, Zhang X, Chang J, et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020;11:1996.
141. Xu X, Zhang J, Wang T, et al. Emerging non-antibody-drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment. Acta Pharm Sin B. 2024;14:1542-59.
142. Xia W, Tao Z, Zhu B, et al. Targeted delivery of drugs and genes using polymer nanocarriers for cancer therapy. Int J Mol Sci. 2021;22:9118.
143. Yao Q, Kou L, Tu Y, Zhu L. MMP-responsive ‘smart’ drug delivery and tumor targeting. Trends Pharmacol Sci. 2018;39:766-81.
144. Bharti C, Gulati N, Nagaich U, Pal A. Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharma Investig. 2015;5:124.
145. Galiana I, Lozano-Torres B, Sancho M, et al. Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. J Controlled Release. 2020;323:624-34.
146. Muñoz-Espín D, Rovira M, Galiana I, et al. A versatile drug delivery system targeting senescent cells. EMBO Mol Med. 2018;10:EMMM201809355.
147. Shi Y, Zhang Y, Zhang Y, et al. Advances in nanotherapy for targeting senescent cells. Int J Nanomed. 2024;19:8797-813.
148. Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Varnamkhasti BS, Saboury AA. Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed Pharmacother. 2019;109:1100-11.
149. Parshad B, Baker AG, Ahmed I, Estepa-Fernández A, Muñoz-Espín D, Fruk L. Improved therapeutic efficiency of senescent cell-specific, galactose-functionalized micelle nanocarriers. Small. 2024;21:2405732.
150. Estepa-Fernández A, Alfonso M, Morellá-Aucejo Á, et al. Senolysis reduces senescence in veins and cancer cell migration. Adv Ther. 2021;4:2100149.
151. Lérida-Viso A, Estepa-Fernández A, Morellá-Aucejo Á, et al. Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice. Pharmacol Res. 2022;183:106356.
152. Watanabe S, Kawamoto S, Ohtani N, Hara E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci. 2017;108:563-9.
153. Ruhland MK, Loza AJ, Capietto A, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016;7:11762.
154. Pan J, Zhang S, Xu Y, et al. A senescent tumor cell-derived nanovesicle directly primes splenic T cells to potentiate cancer radiotherapy. Cell Rep Med. 2026;7:102709.
155. Yang C, Chen Y, Liu J, et al. Leveraging senescent cancer cell membrane to potentiate cancer immunotherapy through biomimetic nanovaccine. Adv Sci. 2024;11:2400630.
156. Han X, Shen S, Fan Q, et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci Adv. 2019;5:eaaw6870.
157. Itchaki G, Brown JR. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. Ther Adv Hematol. 2016;7:270-87.
158. Ichim TE, Lopes G, Reznik R, et al. Reduction of solid tumors by senescent cell immunization. J Transl Med. 2025;23:1365.
159. Kirschner K, Rattanavirotkul N, Quince MF, Chandra T. Functional heterogeneity in senescence. Biochem Soc Trans. 2020;48:765-73.
160. Burd CE, Sorrentino JA, Clark KS, et al. Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model. Cell. 2013;152:340-51.
161. Liu J, Ma X, Cui C, et al. Noninvasive NIR imaging of senescence via in situ labeling. J Med Chem. 2021;64:17969-78.
162. Wu F, Liu J, Tao M, Wang M, Ren X, Hai Z. β-galactosidase-activatable fluorescent and photoacoustic imaging of tumor senescence. Anal Chem. 2023;95:10481-5.
163. Xiang X, Dong C, Zhou L, et al. Novel PET imaging probe for quantitative detection of senescence in vivo. J Med Chem. 2024;67:5924-34.
164. Cen P, Cui C, Huang J, et al. Cellular senescence imaging and senolysis monitoring in cancer therapy based on a β-galactosidase-activated aggregation-induced emission luminogen. Acta Biomater. 2024;179:340-53.
165. Tanaka H, Sugawara S, Tanaka Y, et al. Dipeptidylpeptidase-4-targeted activatable fluorescent probes visualize senescent cells. Cancer Sci. 2024;115:2762-73.
